116344-17-3 Usage
Uses
Used in Pharmaceutical Research and Drug Development:
1-PHENYL-5-PROPYL-1H-PYRAZOLE-4-CARBOXYLIC ACID is used as a key intermediate in the synthesis of new compounds with potential biological activity. Its versatile structure allows for the development of various derivatives, which can be further explored for their therapeutic potential.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 1-PHENYL-5-PROPYL-1H-PYRAZOLE-4-CARBOXYLIC ACID is utilized as a starting material for the design and synthesis of novel drug candidates. Its unique structural features enable the creation of compounds with specific pharmacological properties, making it a promising candidate for the development of innovative therapeutic agents.
Used in Synthesis of Potential Therapeutic Agents:
1-PHENYL-5-PROPYL-1H-PYRAZOLE-4-CARBOXYLIC ACID is employed as a precursor in the synthesis of potential therapeutic agents. Its chemical properties and structural features make it suitable for the development of compounds with diverse pharmacological profiles, which can be further optimized for specific therapeutic applications.
Check Digit Verification of cas no
The CAS Registry Mumber 116344-17-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,6,3,4 and 4 respectively; the second part has 2 digits, 1 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 116344-17:
(8*1)+(7*1)+(6*6)+(5*3)+(4*4)+(3*4)+(2*1)+(1*7)=103
103 % 10 = 3
So 116344-17-3 is a valid CAS Registry Number.
InChI:InChI=1/C13H14N2O2/c1-2-6-12-11(13(16)17)9-14-15(12)10-7-4-3-5-8-10/h3-5,7-9H,2,6H2,1H3,(H,16,17)
116344-17-3Relevant academic research and scientific papers
A novel series of potent and selective small molecule inhibitors of the complement component C1s
Subasinghe, Nalin L.,Ali, Farah,Illig, Carl R.,Rudolph, M. Jonathan,Klein, Scott,Khalil, Ehab,Soll, Richard M.,Bone, Roger F.,Spurlino, John C.,DesJarlais, Renee L.,Crysler, Carl S.,Cummings, Maxwell D.,Morris Jr., Philip E.,Kilpatrick, John M.,Babu, Y. Sudhakara
, p. 3043 - 3047 (2007/10/03)
Activation of the classical pathway of complement has been implicated in disease states such as hereditary angioedema, ischemia-reperfusion injury and acute transplant rejection. The trypsin-like serine protease C1s represents a pivotal upstream point of
